Member Info for Burble

When they have sold out entirely, could we see a rebound?

Wildforce

This was my thought entirely. Either he has got his strategy wrong or I suspect may have other ideas about treatment technologies which he believes are superior and aren't playing ball.

RP very much so. She was not wearing a mask properly, relatively young (I'd say mid 30s) and out and about shopping in town. Surely it's not too much to ask for somebody to stay at home for a few days waiting for their test to come back...surely your Primark trip prior to the pharmacy could have waited.

*************.com/views/51524/covid-spoof-of-the-day-number-one-scancell

Unable to read this as it's behind a paywall, but it sounds like Tom Winnifrith has gripes about C-19 vaccine and SCLP. Would be interested to see if anyone has access

I hope you (and anyone else who needs/wants one) can get one soon.

That's garbage. I'm sorry to hear that. I managed to get mine free through work, but I appreciate that many people who desperately need them are being pushed to the back of the queue. It's frustrating that there has been a massive push for flu vaccination rates, yet there wasn't forethought to ramp up production rates.

I hope so!

Just had my flu vaccine. The shop was evacuated just before my appointment because some moron received their positive Covid test by text message whilst in the store...why oh why don’t people self isolate after having a test until their results come back I won’t know. But the next week is going to be fun. Flu vaccine and possible Covid exposure:

I would happily put my arm on the line for Covidity, or any other of the trials that are ongoing.

Have been registered as a volunteer for C19 clinical trial since the day they opened the form asking for volunteers. Having worked with the clinical trials team and research staff within the NHS, it fills me with confidence to take part here.

So far in my life I’ve taken part in two small trials so far in my life, one was a five day stay At Addenbrooke’s which had five vials of blood being taken every 6 hours. The other I had two punch biopsies done a week apart whilst taking a pill (double blinded so never did find out whether I was on the trial or placebo arm) looking at skin sodium levels whilst taking a new diuretic.

So yes to me being a covid vaccine lab rat. Even more so if it were Covidity.

'and the other is HIV because of its super high mutation rate.'

Just to add to that Inan, coupled to the high mutation rate, the main reason HIV is so difficult to treat is because it infects T-cells - the very thing that you need to engage and target to effectively clear a virally infected cell.

Hindy

True, but there is always scope for second generation vaccines. Manufacturing enough of a single (or handful of) vaccines to immunise the world is going to take time, especially as the real challenge only begins when a vaccine has been approved. This will allow other tortoises in the race to catch up. Furthermore, phase 2 and 3 are only the beginning. Phase 4 (post-market surveillance) may mean that some vaccines start demonstrating adverse effects in particular groups of people, hence may slip down the preferred list.

Add to that things like the cost of manufacture, a DNA vaccine will always be cheaper to produce than a modified virus or protein based therapeutic. Hence, a few pence here or there, suddenly results in vast cost savings for countries in the long run. We also have limited information on the long term protectiveness of many of the vaccines in phase 2 and 3. We may see that their effectiveness drops with time and does not give long lasting protection.

A final thing to add is that even if SCLP is not widely used, if it proves that the Immunobody platform that Covidity is based on is effective at treating and protecting against viral infections, then that opens a massive market area for the company. Demonstrated vaccine against viruses AND cancer.

I'm not too worried that it's a second generation vaccine. There's still plenty of time for the tortoise to catch up and pass the hares in this fight.

Same. Also the benefit of hindsight. I've learned the hard way over the past 10 months to always keep a pot of cash to one side. February time, I hadn't done that and missed the boat on a few different shares I had my eyes on early in this pandemic. Would have made a comfortable retirement fund if I had. Changed my trading strategy to always try and maintain a small pot of cash to one side for those spontaneous investments.

I'd happily take SNG's mid-June share price jump...I believe it was something like 400% overnight. At their peak in mid august their YTD was around 4000% return. We can live in hope.

LL
Synairgen? Isn't it their stock symbol

TLA - three letter acronym?

What a good end to the week!

Lindy et al. have obviously settled on their ideal vaccine construct. It would be really good to see the animal data for this, at least that would allow us to vaguely benchmark us against others. Especially as the FDA has set a relatively low bar (50% effectiveness against placebo https://bit.ly/2ESIwEn).

Something I also wonder is whether further down the line LD will look at it's effectiveness against other coronaviruses (or maybe this has already been done). It is mentioned in the RNS that this may provide effectiveness against others which may arise. I would love to see some data to prove that is the case. Especially seeing as MERS and SARS are still around in the world, this shouldn't be too difficult for somebody down the line to do.

GMP manufacture of DNA is good. Something that stood out is that whilst this RNS talks about manufacturing plasmid, it doesn't mention anywhere about the delivery method. Do we know what that is going to be and whether this has also been manufactured or does that still need doing? Or are they talking about the DNA vaccine in it's entirety (delivery method and payload)?

Am still here just have other things keeping me busy at the moment. Work is v.busy at the moment so have limited time to post. I'm still at work in the office as we speak and have been since 0800 this morning!

Interesting, I’ll have a dig around to see what else is out there either on this or others.

Thank you.

Just trying to work out what the risk to using their party delivery tools is for moditope. As we saw with Ichor, we lost time due to problems on that front which has meant looking elsewhere. I guess this is all part and parcel of complex drug design.

Inan,

Off the top of your head what is the agreement we have with ISA? Is it a global non-exclusive license to use Amplivant?

Just wondering what happens to moditope if we don’t have access to amplivant. Do you anticipate that asset would be purchased by us if Moditope was looking promising or do you anticipate continued use agreements?

Yeah allotment is currently my only escape from life. Normally I’d be elsewhere but team sports aren’t allowed at the moment.

Addendum 3/2/end

Something I hadn’t really also thought through. Moditope relies solely on CD4+ cells. Immunobody on CD4+ and CD8+. Thinking aloud here, as they work through two different mechanisms and would be on two different targets….there may be an opportunity to try them both together.

Imagine this scenario – SCIBx targets molecule Y.

Cancer initially responds to SCIBx as it has molecule Y on it’s surface. If SCIBx doesn’t clear this entirely and the cancer mutates or loses this target on it’s surface, moditope is given to clear up the rest.
or
Cancer responds to Moditope with the booster function of SCIBx as it has molecule Y on it’s surface. If the molecule Y mutates and so SCIBx loses function, there is no need to wait for the cancer to grow and show on scans because moditope has already been given and is working away in the background.

Also think of these in a different light. A lot of people survive their initial cancer, but die of the secondary metastises that may have already seeded themselves around the body. SCIBx would already be searching those out (if they have the target molecule on the surface), moditope may not be needed until the cancer starts really growing and showing the resulting cellular stress-induced post translational modifications. Hence clears up afterwards.